Elevance Health stock: Guggenheim lifts target to USD 460 for Elevance Health stock

Published on 10/16/2026 at 16:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter results are due October 21, 2026 before the open. Elevance Health stock costs EUR 382.35 on October 16, 2026 at 4:10 p.m. CEST.

Analyst target and results date

Guggenheim raised its Elevance Health target to USD 460 from USD 455 on October 12, 2026.
Elevance Health is scheduled to report third-quarter results on October 21, 2026.
Elevance Health stock costs EUR 382.35 at Lang & Schwarz on October 16, 2026 at 4:10 p.m. CEST.
Elevance Health had a market capitalization of USD 92.9 billion and a P/E ratio of 19.03 on October 16, 2026.

Modernes Krankenhaus-Campus mit Glasfassade und Patienten im Eingangsbereich — Elevance Health Krankenversicherungs-Campus US2855211023 zeigt modernen Gebäudeeingang mit weitläufiger Grünanlage unter blauem Himmel, Illustration mit AI erstellt.

Guggenheim raised its Elevance Health price target from USD 455 to USD 460 on October 12, 2026, while keeping a Buy rating, according to Investing.com. Against the USD 428.53 home-market price, the new target stands 7.34 percent higher. Elevance Health stock was trading at EUR 382.35 at Lang & Schwarz on October 16, 2026 at 4:10 p.m. CEST.

Results date sets the next checkpoint

Elevance Health is scheduled to report third-quarter results on October 21, 2026, before the open, according to Gekko. The same preview lists consensus revenue of USD 49.29 billion and earnings per share of USD 4.70 for that report. The date gives the analyst target a near-term test.

Stock stays within its yearly range

The home-market quote was USD 428.53 at 10:25 a.m. ET on October 16, 2026. Elevance Health traded between a 52-week low of USD 274.84 and a high of USD 436.24, placing the latest quote 1.77 percent below the high. Volume was 170,238 shares against an average of 1,145,435 shares.

Valuation and peer comparison

Elevance Health had a market capitalization of USD 92.9 billion and a P/E ratio of 19.03 on October 16, 2026. Its trailing dividend yield was 0.02 percent.

Comparison with peers

Elevance Health: P/E 19.03, market capitalization USD 92.9 billion.

Humana (NYSE, USD): minus 2.67 percent, P/E 39.77, market capitalization USD 50.5 billion.

UnitedHealth Group (NYSE, USD): minus 2.13 percent, P/E 22.73, market capitalization USD 357.2 billion.

What the target means for the stock

The USD 5 increase is modest relative to the USD 460 target, but it gives the stock a dated analyst reference before the results release. Elevance Health reported second-quarter revenue of USD 49.83 billion for the period ended June 30, 2026, according to Gekko. The figure was 0.80 percent higher than a year earlier.

Price view for investors

For investors, the key balance is a USD 460 target against a stock price near the top of its annual range and a results date five days away. The next report will put the USD 49.29 billion revenue estimate and USD 4.70 earnings-per-share estimate into focus.

The further course of trading is shown by the continuously updated real-time quote of Elevance Health stock.